Genomed (WAR:GEN) Research & Development: zł0.00 Mil (TTM As of Mar. 2026)


WAR:GEN Genomed SA WAR:GEN
75 GF Score
Price zł25.80
GF Value zł37.76
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Genomed Research & Development?

Genomed WAR:GEN -2.27% 75 Research & Development is zł0.00 Mil as of Mar. 2026. GuruFocus rates WAR:GEN with a GF Score™ of 75/100 and a GF Value™ of zł37.76 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Genomed's Research & Development for the three months ended in Mar. 2026 was zł0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was zł0.00 Mil.

Genomed  (WAR:GEN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Genomed Research & Development Related Terms

Genomed Research & Development Historical Data

* Premium members only.

The historical data trend for Genomed's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genomed Research & Development Chart

Genomed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Genomed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
WAR:GEN
75GF Score
Genomed SA WAR:GEN
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genomed Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of zł0.00 Mil mean?
Genomed (WAR:GEN) has a Research & Development of zł0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Genomed and its competitors.
Is Genomed's Research & Development too high?
Genomed's current Research & Development is zł0.00 Mil. Overall, Genomed has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomed's Research & Development compare to TMO and DHR?
Genomed's Research & Development of zł0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Diagnostics & Research company?
A good Research & Development depends on the Medical Diagnostics & Research industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Genomed and its competitors. Genomed's current Research & Development is zł0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomed stock overvalued right now?
Based on GuruFocus' analysis, Genomed (WAR:GEN) is currently considered Significantly Undervalued. The stock's GF Value™ is zł37.76, compared to a current price of zł25.80 — trading 31.7% below its estimated fair value. The current Research & Development is zł0.00 Mil. Genomed's overall GF Score™ is 75/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Genomed (WAR:GEN), the current Research & Development is zł0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genomed (WAR:GEN) Overvalued in 2026?

Based on GuruFocus' analysis, Genomed stock appears to be undervalued. The current stock price of zł25.80 is trading 31.7% below its estimated GF Value™ of zł37.76. GuruFocus considers Genomed to be Significantly Undervalued.

Key valuation signals for WAR:GEN:

  • Research & Development: zł0.00 Mil
  • GF Value™: zł37.76 vs. price of zł25.80 (31.7% below fair value)
  • GF Score™: 75/100 with 2 warning signs

No single metric tells the full story. See the WAR:GEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genomed Business Description

Address Ulica Ponczowa 12, Warszawa, POL, 02-971
Genomed SA assembles outstanding molecular biologists and genetic diagnosticians. The company provides diagnostic service that comprises DNA analysis and congenital diseases diagnostics based on DNA sequencing. It offers Diagnostic service and Service for scientific purposes.
75GF Score

Get the complete analysis for WAR:GEN

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł25.80
Price
zł37.76
GF Value